BOTHELL, Wash., Feb. 01, 2023 (GLOBE NEWSWIRE) — Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical firm centered on creating small molecules to revive neuronal well being and sluggish neurodegeneration, immediately introduced the publication of a evaluation paper highlighting the necessity for novel therapy approaches to handle Alzheimer’s illness and the therapeutic potential of fosgonimeton, one of the Firm’s novel small molecule constructive modulators of the HGF/MET system. The evaluation article titled, “The Case for a Novel Therapeutic Approach to Dementia: Small Molecule Hepatocyte Growth Factor (HGF/MET) Positive Modulators,” was printed on-line in the peer-reviewed journal, Journal of Alzheimer’s Illness.
“The lack of therapeutic options for patients suffering from Alzheimer’s disease results in significant economic and societal burdens,” stated Hans Moebius, M.D., Ph.D., Chief Medical Officer of Athira. “In this publication, we review the limitations of the current drug development approaches and discuss the need for additional research efforts that consider the complex AD pathophysiology and incorporate novel study design elements. Taken together, these factors support the advancement of innovative treatment options for Alzheimer’s disease such as Athira’s novel, small molecule positive modulators of the HGF/MET neurotrophic system.”
Within the publication, examine authors famous the pressing have to increase the scope of analysis past the “classic hallmarks” of AD, similar to amyloid-β and tau pathologies, and the rising want for novel approaches to scientific trial design, together with consideration of current insights similar to proteomics to offer a broader characterization of illness processes. The evaluation additionally highlights the therapeutic potential of enhancing the exercise of the HGF/MET neurotrophic system and offers a abstract of the promising preclinical and scientific findings thus far with fosgonimeton, a small molecule constructive modulator of HGF/MET.
“Our preclinical and clinical findings to date support the potential of positive modulation of HGF/MET by fosgonimeton to address factors contributing to neurodegeneration and the resulting loss of cognition and independence,” stated Kevin Church, Ph.D., Chief Scientific Officer of Athira. “This highly specific yet multi-modal intervention may offer a differentiated approach for the clinical development of much needed, innovative therapeutics for Alzheimer’s disease.”
Athira is at the moment evaluating fosgonimeton in the Section 2/3 LIFT-AD examine for mild-to-moderate Alzheimer’s illness. The corporate expects to finish enrollment of the LIFT-AD examine in mid-2023 and to report topline information in early 2024.
The article is out there on the Journal of Alzheimer’s Illness web site and on the Scientific Publications & Displays web page of the corporate’s web site at www.athira.com.
About Fosgonimeton
Fosgonimeton is a small molecule designed to boost the exercise of hepatocyte development issue (HGF) and its receptor, MET, an endogenous restore mechanism for a wholesome nervous system. The perform of the HGF/MET neurotrophic system could also be impaired in situations of neurodegeneration. Concentrating on the safety and restore of neural networks, fosgonimeton has disease-modifying potential to handle a broad vary of neurodegenerative ailments, together with Alzheimer’s and Parkinson’s illness and amyotrophic lateral sclerosis (ALS).
About Athira Pharma, Inc.
Athira Pharma, Inc., headquartered in the Seattle, Washington space, is a late clinical-stage biopharmaceutical firm centered on creating small molecules to revive neuronal well being and sluggish neurodegeneration. Athira goals to offer speedy cognitive enchancment and alter the course of neurological ailments with its novel mechanism of motion. Athira is at the moment advancing its pipeline of therapeutic candidates focusing on the HGF/MET neurotrophic system for Alzheimer’s and Parkinson’s illness, Dementia with Lewy our bodies and amyotrophic lateral sclerosis (ALS). For extra info, go to www.athira.com. You too can observe Athira on Fb, LinkedIn and @athirapharma on Instagram.
Ahead-Trying Statements
This communication incorporates “forward-looking statements” throughout the that means of Part 27A of the Securities Act of 1933, Part 21E of the Securities Change Act of 1934 and the Non-public Securities Litigation Reform Act of 1995. These forward-looking statements should not based mostly on historic reality and embody statements concerning: product candidates as a possible therapy for Alzheimer’s illness, Parkinson’s illness dementia, Dementia with Lewy our bodies, amyotrophic lateral sclerosis , and different neurodegenerative ailments; Athira’s platform know-how and potential therapies; future improvement plans; scientific and regulatory aims and the timing thereof; expectations concerning the potential efficacy and industrial potential of Athira’s product candidates; and Athira’s skill to advance its product candidates into later phases of improvement. Ahead-looking statements typically embody statements which might be predictive in nature and rely on or check with future occasions or situations, and embody phrases similar to “may,” “will,” “should,” “on track,” “would,” “expect,” “plan,” “believe,” “intend,” “pursue,” “continue,” “suggest,” “potential,” and different comparable expressions, amongst others. Any forward-looking statements are based mostly on administration’s present expectations of future occasions and are topic to a quantity of dangers and uncertainties that might trigger precise outcomes to vary materially and adversely from these set forth in or implied by such forward-looking statements. These dangers and uncertainties embody, however should not restricted to, the info for our product candidates from our preclinical and scientific trials not supporting the security, efficacy and tolerability of our product candidates; cessation or delay of Athira’s improvement of product candidates could happen; future potential regulatory milestones for product candidates, together with these associated to present and deliberate scientific research, could also be inadequate to help regulatory submissions or approval; the influence of the COVID-19 pandemic on Athira’s enterprise, analysis and scientific improvement plans and timelines, and the regulatory course of for Athira product candidates; Athira could not be capable to recruit ample sufferers for its scientific trials; the end result of authorized proceedings which have been or could in the longer term be instituted towards us and sure of our administrators and officers; scientific trials could not display security and efficacy of any of Athira’s product candidates; potential detrimental interactions of Athira’s product candidates with different remedies; Athira’s assumptions concerning the sufficiency of its money, money equivalents and investments to fund its deliberate operations could also be incorrect; hostile situations in the final home and international financial markets; the influence of competitors; regulatory businesses could also be delayed in reviewing, commenting on or approving any of Athira’s scientific improvement plans because of this of the COVID-19 pandemic, which might additional delay improvement timelines; the influence of expanded product improvement and scientific actions on working bills; the influence of new or altering legal guidelines and rules; in addition to the opposite dangers detailed in Athira’s filings with the Securities and Change Fee. These forward-looking statements communicate solely as of the date hereof and Athira undertakes no obligation to replace forward-looking statements. Athira could not really obtain the plans, intentions, or expectations disclosed in its forward-looking statements, and you shouldn’t place undue reliance on the forward-looking statements.
Investor & Media Contact
Julie Rathbun
Athira Pharma
Julie.rathbun@athira.com
206-769-9219
0 Comments